Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma

Journal of Dermatology

Volumn 39, Issue 4, 2012, Pages 339-343

  Chen, Yanhui ^a   Chen, Ying ^b   Huang, Liyong ^c   Yu, Jianbin ^d  

^a People's Hospital of Zhengzhou   (China)

^b HENAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (China)

^c First Affiliated Hospital of Xinxiang Medical Colleague   (China)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

cutaneous malignant melanoma; heparanase; immunohistochemistry; junctional nevus; matrix metalloproteinase

Indexed keywords

GELATINASE B; HEPARANASE; PARAFFIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CYTOPLASM; ENZYME DEGRADATION; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA; NEVUS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY;

ADULT; AGED; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MELANOMA; MIDDLE AGED; NEVUS; SKIN NEOPLASMS;

EID: 84858793024     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01441.x     Document Type: Article

References (45)

1. Clark WH, Elder DE, Guerry D, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-1165. (Pubitemid 15128121)
2. Boring CC, Squires TS, Tong T,. Cancer statistics, 1994. CA Cancer J Clin 1994; 44 (1): 7-26.
3. Brown TJ, Nelson BR,. Malignant melanoma: a clinical review. Cutis 1999; 63: 275-278, 281-284.
4. McCawley LJ, Matrisian LM,. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13 (5): 534-540. (Pubitemid 32817010)
5. Pasco S, Ramont L, Maquart FX, et al. Control of melanoma progression by various matrikines from basement membrane macromolecules. Crit Rev Oncol Hematol 2004; 49 (3): 221-233. (Pubitemid 38251354)
6. Hofmann UB, Westphal JR, Van Muijen GN, et al. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115 (3): 337-344.
7. Zhao W, Liu H, Xu S, et al. Migration and metalloproteinases determine the invasive potential of mouse melanoma cells, but not melanin and telomerase. Cancer Lett 2001; 162 (Suppl): S49-S55.
8. Shellman YG, Makela M, Norris DA,. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res 2006; 16 (3): 207-211. (Pubitemid 44085094)
9. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777. (Pubitemid 29449208)
10. Iozzo RV, Murdoch AD,. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 1996; 10: 598-614. (Pubitemid 26141171)
11. Folkman J, D'amore PA,. Blood vessel formation: what is its molecular basis? Cell 1996; 87: 1153-1155. (Pubitemid 27010098)
12. Iozzo RV, Karmanos N,. Proteoglycans in health and disease: emerging concepts and future directions. FEBS J 2010; 277 (19): 3863.
13. Iriyamas S, Matsunaga Y, Amano S,. Heparanase activation induces epidermal hyperplasia, angiogenesis, lymphangiogenesis and wrinkles. Exp Dermatol 2010; 19 (11): 965-972.
14. Tellez CS, Davis DW, Prieto VG, et al. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2 [alpha] and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol 2006; 127: 387-393. (Pubitemid 46106918)
15. Gray-Schopfer V, Wellbrock C, Marais R,. Melanoma biology and new targeted therapy. Nature 2007; 445: 851-857.
16. Blackburn JS, Liu I, Coon CL, et al. A matrix metalloproteinase-1/ protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009; 28 (48): 4237-4248.
17. Fingleton B,. Maxtrix metalloproteinases: roles in cancer and metastasis. Front Biosci 2006; 11: 479-491. (Pubitemid 43258157)
18. Dempsey LA, Brunn GJ, Platt JL,. Heparanase, a potent regulator of cell matrix interactions. Trends Biochem Sci 2000; 25: 349-355.
19. Van Denoord JJ, Paemen L, Opdenakker G, et al. Expression of gelatinase B and extracellular matrix metalloproteinase inducer EMMPRIM in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-670. (Pubitemid 27385597)
20. Macdougall JR, Bani MR, Lin Y, et al. Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B expression. Br J Cancer 1999; 80: 504-512. (Pubitemid 29213207)
21. Hofmann UB, Eggert AAO, Blass K, et al. Expression of matrix metalloproteinase in the microenviroment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 2003; 63: 8221-8225. (Pubitemid 37549471)
22. Ilan N, Elkin M, Vlofavsky I,. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 2006; 38: 2018-2039. (Pubitemid 44397619)
23. Mckenzie EA,. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 2007; 151: 1-14. (Pubitemid 46675998)
24. Miao HQ, Liu H, Navarro E, et al. Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 2006; 13: 2101-2111. (Pubitemid 44132602)
25. Vlodavsky I, Abboud-Jarrous G, Elkin M, et al. The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb 2006; 35: 116-127.
26. Roy M, Reiland J, Murry BP, et al. Antisense-mediated suppression of heparanase gene inhibits melanoma cell invasion. Neoplasia 2005; 7: 253-262. (Pubitemid 40411637)
27. Roy M, Marchetti D,. Cell surface heparin sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem 2009; 106 (2): 200-209.
28. Hulett MD, Hornby JR, Ohms SJ, et al. Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 2000; 39 (51): 15659-15667. (Pubitemid 32038227)
29. Fairbanks MB, Mildner AM, Leone JW, et al. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J Biol Chem 1999; 274: 29587-29590.
30. Kussie PH, Hulmes JD, Ludwig DL, et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 1999; 261: 183-187. (Pubitemid 29371638)
31. Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802. (Pubitemid 29318614)
32. Fux L, Ilan N, Sanderson RD, et al. Heparanase: busy at the cell surface. Trends Biochem Sci 2009; 34: 511-519.
33. Cohen-Kaplan V, Naroditsky I, Zetser A, et al. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 2008; 123: 2566-2573.
34. Barash U, Cohen-Kaplan V, Dowek I, et al. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010; 277: 3890-3903.
35. Purushiothaman A, Chen L, Yang Y, et al. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283: 32628-32636.
36. Raghu H, Sodadasu PK, Malla RR, et al. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010; 10: 647.
37. Bex-Zaken O, Gingis-Velitski S, Vlodavsky I, et al. Heparanse induces AKT phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 2007; 361 (4): 829-834. (Pubitemid 47259014)
38. Fux L, Feibish N, Cohen-Kaplan V, et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 2009; 69: 1758-1767.
39. Doweck I, Cohen-Kaplan V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006; 8: 1055-1061. (Pubitemid 44936155)
40. Lee JH, Pyon JK, Kim DW, et al. Elevated c-Src and c-Yes expression in malignant skin cancers. J Exp Clin Cancer Res 2010; 29: 116.
41. Kunigal S, Lakka SS, Gondi CS, et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121: 2307-2316. (Pubitemid 47585614)
42. Lu MK, Shih YW, Chang Chien TT, et al. α-solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2/9 activaties. Biol Pharm Bull 2010; 33 (10): 1685-1691.
43. Gingis-Velitski S, Zetser A, Flugelman MY, et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279 (22): 23536-23541. (Pubitemid 38685666)
44. Zcharia E, Jia J, Zhang X, et al. Newly generated hepa- ranase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009; 4: e5181.
45. Ossowski L, Aguirre-Ghiso JA,. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 2010; 23 (1): 41.